Chondroitin sulfate is a natural mucopolysaccharide. Shark Chondroitin is mainly used in the production of health products and drugs to treat Osteoarthritis. In addition, due to its strong water absorption, there are also related products in cosmetics, eye drops, and other fields. In recent years, the treatment field has further expanded to the hearing impairment caused by Streptomycin and the auxiliary treatment of hepatitis, some neurological headache, migraine, anticoagulation and antithrombotic, and the treatment of oral mucosal ulcer.
overseas market
The popularity of bone and joint dietary supplements in foreign markets is relatively high, and the market growth rate has slowed down, maintaining a natural growth rate. In 2015, the market size of bone and joint dietary supplements in the United States and Japan was $1.7 billion and $990 million, respectively. Among them, Chondroitin sulfate accounts for about 50%. In addition to the EU market, the market size of Chondroitin sulfate dietary supplements is about US $2 billion.
In terms of drugs, the best-selling anti Osteoarthritis product in the U.S. market is the Chondroitin sulfate+Glucosamine compound capsule. In 2016, its market size was about $3 billion, and the global anti Osteoarthritis product market size was about $5.5 billion.
domestic market
According to the prediction of the Population Research Institute of East China Normal University, the elderly population in China will reach 230 million by 2020, accounting for 15.98% of the total population; By 2030, the elderly population in China will reach 310 million, accounting for 20.42% of the total population; By 2050, the elderly population will reach 468 million, accounting for 27.71% of the total population. The incidence rate of Osteoarthritis is closely related to age. In 2016, the prevalence rate of arthritis in China was 8.1%, and the number of patients was about 100 million. With the aging of the population, the prevalence rate of arthritis will continue to rise in the future.
In the field of health products, due to the lack of functional claims for bones and joints in the current health food function statements in China, a large number of bone and joint health products adopt the function claim of "increasing bone density" as a substitute. The error in this function claim has led to a misunderstanding of Chinese consumers' understanding of bone and joint health products. The market size of domestic bone and joint health products is relatively small, and the popularity rate is low.
At present, Jianlido, a subsidiary of Tomson Beijian, accounts for over 50% of the share of bone and joint health products. In the first half of 2017, the revenue scale was around 100 million yuan, and the annual revenue was around 200 million yuan. Based on this, it is estimated that the industry scale of bone and joint health products is around 400 million yuan, which is relatively small.
Although the industry scale is still small, health product companies represented by Thomson Bejian have increased their efforts to explore the bone and joint health product market. In 2017, Jianli Polysaccharides products became a variety of Thomson Bejian's major single product strategy. In the future, the company announced that it would concentrate and mobilize market advantage resources, actively explore the bone and joint health product market, and it is expected that the space for bone and joint health products will gradually open up in the future.
